↓ Skip to main content

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
Published in
Journal for Immunotherapy of Cancer, September 2018
DOI 10.1186/s40425-018-0400-4
Pubmed ID
Authors

Guacimara Ortega Sanchez, Kathleen Jahn, Spasenija Savic, Alfred Zippelius, Heinz Läubli

Abstract

The development of pulmonary immune-related adverse events (irAEs) in patients undergoing PD-(L)1 targeted checkpoint inhibitors are rare, but may be life-threatening. While many published articles and guidelines are focusing on the presentation and upfront treatment of pulmonary irAEs, the strategy in patients with late-onset pneumonia that are resistant to commonly used immunosuppressive drugs remains unclear. Here, we report the successful treatment of a mycophenolate-resistant organizing pneumonia (OP) with infliximab in a patient with metastatic melanoma after PD-1 blockade. The patient received two years of PD-1 targeted immunotherapy when he developed multiple nodular lung lesions mimicking a metastatic progression. However, wedge resection of these lesions showed defined areas of OP, which responded well to corticosteroids. Upon tapering, new foci of OP developed which were resistant to high-dose steroids and mycophenolate treatment. The TNFα antagonist infliximab led to a rapid and durable regression of the inflammatory lesions. This case describes a not well-studied situation, in which a mycophenolate-resistant PD-1 blocker-associated pneumonitis was successfully treated with a TNFα neutralizing antibody. The outcome of this case suggests that infliximab might be the preferable option compared to classical immunosuppressants in the case of steroid-resistant/-dependent late onset pulmonary irAEs.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 35%
Student > Postgraduate 2 10%
Student > Ph. D. Student 2 10%
Professor 1 5%
Student > Master 1 5%
Other 2 10%
Unknown 5 25%
Readers by discipline Count As %
Medicine and Dentistry 7 35%
Immunology and Microbiology 2 10%
Neuroscience 2 10%
Social Sciences 1 5%
Unspecified 1 5%
Other 0 0%
Unknown 7 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2018.
All research outputs
#7,767,677
of 13,549,479 outputs
Outputs from Journal for Immunotherapy of Cancer
#645
of 818 outputs
Outputs of similar age
#135,718
of 263,607 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 13,549,479 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 818 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.5. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,607 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them